Highlights Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Delayed Nasdaq Other stock markets 12:33:32 11/05/2024 am IST			5-day change	1st Jan Change
2.552 ^USD	-6.18%		-13.35%	+6.56%

09/05	Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
23/04	Lixte Biotechnology Files Up to $50 Million Mixed Shelf	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal	27/03	CI
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	21/03	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03	CI
LIXTE Biotechnology Holdings, Inc. Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	26/02	CI
Lixte Biotechnology Holdings, Inc. Announces Dosing of the First Patient in A Phase 1B/2 Clinical Trial to Assess Whether Adding Lixte?S Lb-100 to Gsk?S Programmed Death Receptor-1 (Pd-1)-Blocking Monoclonal Antibody, Dostarlimab-Gxly, May Enhance the Effectiveness of Immunotherapy in the Treatment of Ovarian Clear Cell Carcinoma	29/01	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
LIXTE Biotechnology Holdings, Inc. Announces Supported Collaborative Trial to Study LIXTE?s First-in-Class PP2A Inhibitor, LB-100, Plus GSK?s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer	20/23/20	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Lixte Biotechnology Regains Nasdaq Compliance	23/23/23	MT
LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol	07/23/07	CI
Lixte Biotechnology Implements 1-for-10 Reverse Stock Split	02/23/02	MT
Lixte Biotechnology Holdings, Inc. Announces Recently Published Independent Research Reveals New Mechanisms	30/23/30	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
LIXTE Biotechnology Holdings, Inc. Reports First Spanish Site Activated to Begin Accrual of Patients for A Phase 1b/2 Clinical Trial of LIXTE's Lead Anti-Cancer Compound, Added to Doxorubicin as First-Line Treatment of Advanced Soft Tissue Sarcoma	26/23/26	CI
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial	05/23/05	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	29/23/29	CI
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/22/08	CI
LIXTE Biotechnology Gets Approval for Soft Tissue Sarcomas Treatment Trial	13/22/13	MT
LIXTE Biotechnology Holdings, Inc. Announces Spanish Agency for Medicines and Health Products Authorized Phase 1b/Randomized Phase 2 Study of LB-100	13/22/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lixte Biotechnology Holdings, Inc.

Equities

LIXT

US5393193017

Highlights

Filters